Home > News > Introgen applies to market Advexin in Europe
November 13th, 2007
Introgen applies to market Advexin in Europe
Abstract:
Introgen Therapeutics Inc. and its subsidiary, Gendux Molecular Ltd., have submitted a marketing authorization application to the European Medicines Agency for Advexin, a tumor suppressor therapy for use in the treatment of a type of cancer known as Li-Fraumeni Syndrome.
Austin-based Introgen (NASDAQ: INGN) has offices housing a clinical and regulatory development staff of about 70 in the Texas Medical Center plus a manufacturing facility nearby.
A year ago, the biotech company obtained an exclusive worldwide license to a portfolio of patents from The University of Texas M.D. Anderson Cancer Center, along with agreements to commercialize products based on the licensed technologies. Those patents are focused on the delivery of biologically active proteins, polypeptides and peptides on the nanoparticle level.
Source:
bizjournals.com
Bookmark:
| Related News Press |
Nanomedicine
Ben-Gurion University of the Negev researchers several steps closer to harnessing patient's own T-cells to fight off cancer June 6th, 2025
Cambridge chemists discover simple way to build bigger molecules – one carbon at a time June 6th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Self-propelled protein-based nanomotors for enhanced cancer therapy by inducing ferroptosis June 6th, 2025
Announcements
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Quantum computers simulate fundamental physics: shedding light on the building blocks of nature June 6th, 2025
A 1960s idea inspires NBI researchers to study hitherto inaccessible quantum states June 6th, 2025
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||